TN2011000163A1 - Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine - Google Patents

Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine

Info

Publication number
TN2011000163A1
TN2011000163A1 TN2011000163A TN2011000163A TN2011000163A1 TN 2011000163 A1 TN2011000163 A1 TN 2011000163A1 TN 2011000163 A TN2011000163 A TN 2011000163A TN 2011000163 A TN2011000163 A TN 2011000163A TN 2011000163 A1 TN2011000163 A1 TN 2011000163A1
Authority
TN
Tunisia
Prior art keywords
vincristine
containing antibodies
antibodies recognizing
combinations containing
recognizing specifically
Prior art date
Application number
TN2011000163A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TN2011000163A1 publication Critical patent/TN2011000163A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TN2011000163A 2008-11-28 2011-04-07 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine TN2011000163A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291117A EP2191841A1 (fr) 2008-11-28 2008-11-28 Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
PCT/IB2009/055390 WO2010061358A1 (fr) 2008-11-28 2009-11-27 Associations antitumorales contenant des anticorps reconnaissant spécifiquement cd38 et de la vincristine

Publications (1)

Publication Number Publication Date
TN2011000163A1 true TN2011000163A1 (en) 2012-12-17

Family

ID=40627439

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000163A TN2011000163A1 (en) 2008-11-28 2011-04-07 Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine

Country Status (31)

Country Link
US (1) US8633301B2 (fr)
EP (2) EP2191841A1 (fr)
JP (2) JP2012510462A (fr)
KR (1) KR101733253B1 (fr)
CN (1) CN102264388B (fr)
AR (1) AR074220A1 (fr)
AU (1) AU2009321250B2 (fr)
BR (1) BRPI0922304B1 (fr)
CA (1) CA2744996C (fr)
CL (1) CL2011001255A1 (fr)
CO (1) CO6361946A2 (fr)
CR (1) CR20110281A (fr)
DO (1) DOP2011000118A (fr)
EA (1) EA026092B1 (fr)
EC (1) ECSP11011064A (fr)
HK (1) HK1164153A1 (fr)
HN (1) HN2011001420A (fr)
IL (1) IL213117A (fr)
MA (1) MA32895B1 (fr)
MX (1) MX2011005539A (fr)
NI (1) NI201100106A (fr)
NZ (1) NZ592992A (fr)
PA (1) PA8850001A1 (fr)
PE (1) PE20110821A1 (fr)
SG (1) SG171822A1 (fr)
TN (1) TN2011000163A1 (fr)
TW (1) TWI457124B (fr)
UA (1) UA105507C2 (fr)
UY (1) UY32265A (fr)
WO (1) WO2010061358A1 (fr)
ZA (1) ZA201103923B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (fr) 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
KR101912957B1 (ko) * 2010-09-27 2018-10-29 모르포시스 아게 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
PT2900232T (pt) 2012-09-25 2018-02-09 Morphosys Ag Combinações e suas utilizações
TN2016000142A1 (en) * 2013-10-31 2017-10-06 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers.
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2015200626A1 (fr) * 2014-06-25 2015-12-30 The Rockefeller University Compositions et procédés pour la production rapide de répertoires polyvalents de nanocorps
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
EP3227338A4 (fr) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anticorps anti-cd38 pour le traitement de la leucémie aiguë myéloïde
AU2016264725B2 (en) 2015-05-20 2021-05-27 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
WO2016197204A1 (fr) * 2015-06-11 2016-12-15 Bionomics Limited Association pharmaceutique et utilisations de cette association
JP6816038B2 (ja) 2015-06-22 2021-01-20 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
CA3079242A1 (fr) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methodes de traitement du myelome multiple a haut risque
AU2020242228A1 (en) 2019-03-15 2021-07-22 Morphosys Ag Anti-CD38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) 2019-11-29 2022-08-16 康诺亚生物医药科技(成都)有限公司 药物组合物及其制备方法和应用
KR20220159947A (ko) 2019-12-05 2022-12-05 사노피-아벤티스 유.에스. 엘엘씨 피하 투여를 위한 항-cd38 항체의 제형
AU2022208200A1 (en) 2021-01-14 2023-07-20 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗cd38抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
RU2224766C2 (ru) 1997-04-14 2004-02-27 Микромет Аг Способ получения рецепторов для человеческих антигенов и их применение
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU770718B2 (en) * 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1720907B1 (fr) 2004-02-06 2015-04-08 MorphoSys AG Anticorps humains anti-cd38 et utilisations de ceux-ci
SI2567976T1 (sl) * 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
SI2081595T1 (sl) * 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus kortikosteroidi plus ne-kortikosteroidni kemoterapevtik za zdravljenje tumorjev
US20080092384A1 (en) * 2006-10-16 2008-04-24 Schaake Mark D Installation of Middle Bearing for a Crankshaft
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer

Also Published As

Publication number Publication date
AU2009321250A1 (en) 2010-06-03
BRPI0922304B1 (pt) 2022-08-09
KR101733253B1 (ko) 2017-05-08
ZA201103923B (en) 2012-09-26
HK1164153A1 (en) 2012-09-21
EP2191841A1 (fr) 2010-06-02
JP2015172049A (ja) 2015-10-01
NZ592992A (en) 2012-12-21
NI201100106A (es) 2011-09-26
TW201024310A (en) 2010-07-01
JP2012510462A (ja) 2012-05-10
EA201100867A1 (ru) 2011-10-31
MX2011005539A (es) 2011-10-10
EP2370095A1 (fr) 2011-10-05
US8633301B2 (en) 2014-01-21
CL2011001255A1 (es) 2012-01-27
KR20110091785A (ko) 2011-08-12
ECSP11011064A (es) 2011-07-29
AR074220A1 (es) 2010-12-29
DOP2011000118A (es) 2011-06-30
TWI457124B (zh) 2014-10-21
CO6361946A2 (es) 2012-01-20
US20110293606A1 (en) 2011-12-01
HN2011001420A (es) 2014-01-13
PE20110821A1 (es) 2011-11-19
MA32895B1 (fr) 2011-12-01
CA2744996A1 (fr) 2010-06-03
JP6130871B2 (ja) 2017-05-17
EA026092B1 (ru) 2017-03-31
CR20110281A (es) 2011-12-07
CN102264388A (zh) 2011-11-30
UA105507C2 (uk) 2014-05-26
WO2010061358A1 (fr) 2010-06-03
PA8850001A1 (es) 2010-07-27
CN102264388B (zh) 2014-07-16
BRPI0922304A2 (pt) 2016-06-21
UY32265A (es) 2010-06-30
CA2744996C (fr) 2019-05-07
EP2370095B1 (fr) 2020-04-01
SG171822A1 (en) 2011-07-28
AU2009321250B2 (en) 2016-05-26
IL213117A (en) 2017-08-31
IL213117A0 (en) 2011-07-31

Similar Documents

Publication Publication Date Title
TN2011000163A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
MY166530A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamide
TN2011000232A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 melphalan
TN2011000242A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
TN2013000245A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide